Fri, Dec 19, 2014, 10:53 AM EST - U.S. Markets close in 5 hrs 7 mins


% | $
Quotes you view appear here for quick access.

Qihoo 360 Technology Co. Ltd. Message Board

rochelle535 9 posts  |  Last Activity: Dec 2, 2014 1:40 PM Member since: May 28, 2009
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    I have no idea what's happening and that's OK

    by bharry413 Dec 2, 2014 12:15 PM
    rochelle535 rochelle535 Dec 2, 2014 1:40 PM Flag

    You might want to look at the size of the trial. Really only 10 patients. that's not enough to mean anything. I can't help wondering why, after all this time, and the large quantity of people who have hep c in india, they only got that many patients to complete the protocol. And of the 10 really only 8 had the stellar results. I can't help wondering what happened to the rest of the patients. Trial results are not really that significant due to size of the sample. Be careful here. This company hypes everything up to make it seem more than it is. I would wait for a dip which will come and come big, before buying in. in the twenties would be good entry point.

  • Reply to


    by losingmyask Nov 24, 2014 10:29 AM
    rochelle535 rochelle535 Nov 26, 2014 9:18 AM Flag

    Well it looks like news is out but there were only 9 patients. Only 9 in all that time? Hmmm.
    And everyone thought 43 patients that cytosorbents trial had were woefully short of meaningful. I say it's a lot of hype coming from Aethlon and little substance. Not nearly enough evidence to mean anything. And, if a third of India's population, or something like that, have Hep C, why only 9 patients after all this time? Something not right there.

  • Reply to


    by ronvitalez Nov 26, 2014 8:40 AM
    rochelle535 rochelle535 Nov 26, 2014 9:00 AM Flag

    If this isn't fluff pr tell me what is.

  • rochelle535 rochelle535 Nov 26, 2014 8:46 AM Flag

    Where are you getting this information? It's not on the website and it's not there.

  • Reply to


    by losingmyask Nov 24, 2014 10:29 AM
    rochelle535 rochelle535 Nov 24, 2014 12:05 PM Flag

    The runup in AEMD is due to lots of enthusiasm and little else. This company has no money and the product was used on 1 ebola patient where it can't be determined how much of the recovery was due to the product and how much to everything else (including drugs) the patient was given. They have no marketable product yet. The FDA approval process is just starting for Hep C which is the large market. The Ebola market, while it draws lots of attention, is not a large market and is not usually even any market at all. But enthusiasm trumps everything. This will capitulate as reality sets in. How many times has enthusiasm pumped up the price of a stock only to have it come crashing down again?

  • rochelle535 rochelle535 Nov 19, 2014 7:43 AM Flag

    You have to realize that treating ebola in the u.s. is not a big money maker. There are hardly any cases here. In Africa, they lack the necessary dialysis machines in all the rural clinics the patients are going to so there's no way to use the filter extensively over there. how many patients can be transported to Germany for treatment either? I agree completely that the filter has tremendous potential for unmet clinical needs relative to viruses that are currently untreatable. However, this company has no money and is at least 2 years away from any meaningful commercialization. That's why these spikes in price happen with lots of enthusiasm but that's all it is. There are no fundamentals yet to justify it. therefore the price goes up and then goes down.

  • Reply to

    RECESS Trial Results?

    by slappe_was Oct 28, 2014 8:18 AM
    rochelle535 rochelle535 Oct 28, 2014 12:00 PM Flag

    if this info is in fact related to the recess trial then this is very GOOD news because previous studies have found increased complications and mortality when patients were given older blood versus fresh blood. With the constant shortage of newer or fresh blood it would be great if there was a way to use old blood and have no worse outcomes than with new blood. That's the point guys!

  • Reply to

    Adam Feurstein....

    by ctso4life Oct 17, 2014 12:46 PM
    rochelle535 rochelle535 Oct 17, 2014 3:36 PM Flag

    I went back and read the study again and the 10Q. It doesn't say what this guy is representing. Not sure why he is saying what he's saying. Yes the original study was small and yes they excluded half the participants because, as they mentioned, those patients did not satisfy the requirements to insure the patient population was homogeneous. And, let's look at sales. It's been long enough now that we know the thing works or there wouldn't be any sales. Some of the most prestigious medical facilities in Germany are using it and ordering more. They wouldn't do that if it didn't work. Yes, it probably doesn't help everyone but then nothing works on everyone. So, let's not get all caught up in what this guy says. He usually covers drugs and what is required to sell drugs is not the same as what is required to sell medical devices especially if the device has been shown to be completely safe as this one has. I think Adam should stick to what he knows because he obviously doesn't know much about this.

  • Reply to

    Life is Really Sucking Right Now!!!

    by jaxla Sep 26, 2014 1:03 PM
    rochelle535 rochelle535 Sep 29, 2014 10:17 AM Flag

    Since they now have several distributors it is more difficult to estimate sales since some of it is not direct. Earlier when sales were all diect it was easy to estimate.

58.54-0.15(-0.26%)10:53 AMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.